Exclusive low-dose-rate brachytherapy in 279 patients with T2N0 mobile tongue carcinoma
Abstract
Purpose: To evaluate the therapeutic results obtained with {sup 192}Ir low-dose-rate interstitial brachytherapy in T2N0 mobile tongue carcinoma. Patients and Methods: Between December 1979 and January 1998, 279 patients with T2N0 mobile tongue carcinoma were treated by exclusive low-dose-rate brachytherapy, with or without neck dissection. {sup 192}Ir brachytherapy was performed according to the 'Paris system' with a median total dose of 60 Gy (median dose rate, 0.5 Gy/h). Results: Overall survival was 74.3% and 46.6% at 2 and 5 years. Local control was 79.1% at 2 years and regional control, respectively, 75.9% and 69.5% at 2 and 5 years (Kaplan-Meier method). Systematic dissection revealed 44.6% occult node metastases, and histologic lymph node involvement was identified as the main significant factor for survival. Complication rate was 16.5% (Grade 3, 2.9%). Half of the patients presented previous and/or successive malignant tumor (ear-nose-throat, esophagus, or bronchus). Conclusion: Exclusive low-dose-rate brachytherapy is an effective treatment for T2 tongue carcinoma. Regional control and survival are excellent in patients undergoing systematic neck dissection, which is mandatory in our experience because of a high rate of occult lymph node metastases.
- Authors:
-
- Department of Radiotherapy, Centre Oscar Lambret, Lille (France)
- Department of Biostatistics, Centre Oscar Lambret, Lille (France)
- Department of Head and Neck Surgery, Centre Oscar Lambret, Lille (France)
- Publication Date:
- OSTI Identifier:
- 20702151
- Resource Type:
- Journal Article
- Journal Name:
- International Journal of Radiation Oncology, Biology and Physics
- Additional Journal Information:
- Journal Volume: 63; Journal Issue: 2; Other Information: DOI: 10.1016/j.ijrobp.2005.02.014; PII: S0360-3016(05)00350-0; Copyright (c) 2005 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA); Journal ID: ISSN 0360-3016
- Country of Publication:
- United States
- Language:
- English
- Subject:
- 62 RADIOLOGY AND NUCLEAR MEDICINE; AUDITORY ORGANS; BRACHYTHERAPY; CARCINOMAS; DOSE RATES; ESOPHAGUS; IRIDIUM 192; LYMPH NODES; METASTASES; NECK; NOSE; PATIENTS; PHARYNX; RADIATION DOSES; TONGUE
Citation Formats
Bourgier, Celine, Coche-Dequeant, Bernard, Fournier, Charles, Castelain, Bernard, Prevost, Bernard, Lefebvre, Jean-Louis, and Lartigau, Eric. Exclusive low-dose-rate brachytherapy in 279 patients with T2N0 mobile tongue carcinoma. United States: N. p., 2005.
Web. doi:10.1016/j.ijrobp.2005.02.014.
Bourgier, Celine, Coche-Dequeant, Bernard, Fournier, Charles, Castelain, Bernard, Prevost, Bernard, Lefebvre, Jean-Louis, & Lartigau, Eric. Exclusive low-dose-rate brachytherapy in 279 patients with T2N0 mobile tongue carcinoma. United States. https://doi.org/10.1016/j.ijrobp.2005.02.014
Bourgier, Celine, Coche-Dequeant, Bernard, Fournier, Charles, Castelain, Bernard, Prevost, Bernard, Lefebvre, Jean-Louis, and Lartigau, Eric. 2005.
"Exclusive low-dose-rate brachytherapy in 279 patients with T2N0 mobile tongue carcinoma". United States. https://doi.org/10.1016/j.ijrobp.2005.02.014.
@article{osti_20702151,
title = {Exclusive low-dose-rate brachytherapy in 279 patients with T2N0 mobile tongue carcinoma},
author = {Bourgier, Celine and Coche-Dequeant, Bernard and Fournier, Charles and Castelain, Bernard and Prevost, Bernard and Lefebvre, Jean-Louis and Lartigau, Eric},
abstractNote = {Purpose: To evaluate the therapeutic results obtained with {sup 192}Ir low-dose-rate interstitial brachytherapy in T2N0 mobile tongue carcinoma. Patients and Methods: Between December 1979 and January 1998, 279 patients with T2N0 mobile tongue carcinoma were treated by exclusive low-dose-rate brachytherapy, with or without neck dissection. {sup 192}Ir brachytherapy was performed according to the 'Paris system' with a median total dose of 60 Gy (median dose rate, 0.5 Gy/h). Results: Overall survival was 74.3% and 46.6% at 2 and 5 years. Local control was 79.1% at 2 years and regional control, respectively, 75.9% and 69.5% at 2 and 5 years (Kaplan-Meier method). Systematic dissection revealed 44.6% occult node metastases, and histologic lymph node involvement was identified as the main significant factor for survival. Complication rate was 16.5% (Grade 3, 2.9%). Half of the patients presented previous and/or successive malignant tumor (ear-nose-throat, esophagus, or bronchus). Conclusion: Exclusive low-dose-rate brachytherapy is an effective treatment for T2 tongue carcinoma. Regional control and survival are excellent in patients undergoing systematic neck dissection, which is mandatory in our experience because of a high rate of occult lymph node metastases.},
doi = {10.1016/j.ijrobp.2005.02.014},
url = {https://www.osti.gov/biblio/20702151},
journal = {International Journal of Radiation Oncology, Biology and Physics},
issn = {0360-3016},
number = 2,
volume = 63,
place = {United States},
year = {Sat Oct 01 00:00:00 EDT 2005},
month = {Sat Oct 01 00:00:00 EDT 2005}
}